Budesonide inhalation - Aquilon Pharma
Alternative Names: AQ-001SLatest Information Update: 23 Mar 2023
At a glance
- Originator Aquilon Pharma
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II SARS-CoV-2 acute respiratory disease
- Phase I/II Asthma
Most Recent Events
- 31 Jan 2023 Aquilon Pharmaceuticals completes the I/II BOREAS trial in Asthma in Belgium (NCT04933383; EudraCT2019-002849-38)
- 21 Dec 2022 Aquilon Pharmaceuticals terminates a phase-II trial in SARS-COV-2 acute respiratory disease in Belgium (Inhalation) due to lack of patient enrolment (EudraCT2021-000014-42; NCT05000346)
- 21 Feb 2022 Aquilon Pharmaceuticals completes the BORA trial in SARS-COV-2 acute respiratory disease (In volunteers) in Bulgaria (Inhalation) (NCT05148312)